Trial
NCT01029925
Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
Jonsson Comprehensive Cancer Center
Collaborators
—
Condition
Metastatic Breast Cancer
Intervention
Dichloroacetate (DCA)
Why stopped
DSMB determined, due to higher than expected risk/safety concerns, study should be closed.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-02-12